1953-04-4 Galantamine hydrobromide AKSci J10353
 
 
Loading Please Wait...
  J10353    
Galantamine hydrobromide, >98% (HPLC)
 
Nivalin
Razadyne
IDENTITY
CAS Number:1953-04-4
MDL Number:MFCD00067672
MF:C17H22BrNO3
MW:368.27
EINECS:217-780-5
BRN:3787265
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:256°C
Optical Rotation:-92.0 to -98.0° (c=1.4, H2O)
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:III
A hazmat fee may apply to certain package sizes. Please check pricing table for an indicator of applicable hazmat fees.

BIOLOGICAL INFO
Solubility:Water: 20mg/mL; Soluble in ethanol
Application(s):Reversible acetylcholinesterase inhibitor

REVIEW
 Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine''s proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.

REFERENCES
[1]Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer''s disease. Drugs. 2000 Nov;60(5):1095-122.
[2] Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6.
[3] Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6.
[4] Birks J: Cholinesterase inhibitors for Alzheimer''s disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Pubmed# Lilienfeld S: Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer''s disease. CNS Drug Rev. 2002 Summer;8(2):159-76.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H301

Precautionary Statements
P264; P270; P301+P310; P321; P330; P405; P501

Current as of April 30, 2024


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.


CATEGORIES
 APIs and Bioactives > AChR Agonists, Alzheimer's


PubChem